Health · Pharma & Biotech · 6 hrs ago
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
A drug that blocks PDE9 is being developed as a possible treatment for heart failure.
Two phase II trials compared the drug with a placebo, which has no active medicine.
The trials involved heart failure with reduced ejection fraction, a form of the condition.
Researchers suspect both trials may have tested the wrong dose.
That raises questions about what the trials can show about the drug.
The possible dosing problem is a major setback for its development.
The drug’s development is back at the drawing board, but no next steps are described.
Development of a PDE9 inhibitor for heart failure hit a major roadblock.
Two phase II placebo-controlled trials were suspected of testing the wrong dose.
The source identifies the setting as Phoenix.
MedPage Today published the report on October 11, 2026.
- Who
- The developers and trial investigators are not stated.
- What
- Two phase II placebo-controlled trials of a PDE9 inhibitor for heart failure were suspected of testing the wrong dose.
- When
- MedPage Today published the report on October 11, 2026; the trial dates are not stated.
- Where
- Phoenix.
- Why
- The trials were suspected of having tested the wrong dose.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Drug target
- PDE9 inhibitor
- Condition
- Heart failure
- Trials
- Two phase II placebo-controlled trials
- Publication date
- October 11, 2026
Sources
Related news
Dong-A launches three ibuprofen-based cold medicines
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Spain withdraws five erectile dysfunction supplements containing undeclared drugs
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental eye drops improve vision in a small study of a rare eye disease
Taboos limit sales of weight-loss drugs in India despite obesity rates
